Anti-Aging Drugs Under the Microscope: Metformin, Rapamycin and NMN
Three researchers take apart the most hyped longevity molecules one by one: metformin, rapamycin, NMN/NR, niacin and a handful of supplements. The recurring verdict is uncertainty in humans — impressive animal data rarely survives the jump to people, and some interventions carry real downsides. The consistent message: get the big levers right before playing at the edges.
Overview
The conversation opens with a blunt observation: in the aging field, the ratio of science to hype can be as lopsided as 1 to 99. Metformin serves as the cautionary tale — early results in one inbred mouse strain and observational diabetes data drove enormous excitement, but a replication program running the same experiment across three labs with genetically diverse mice found no lifespan extension, and a 21-year human prevention trial showed no benefit for mortality, cancer or cardiovascular disease.
Worse, two randomized trials suggest metformin blunts roughly half the exercise benefit for VO2 max and strength in non-diabetics, and it lowers testosterone. Rapamycin is treated more generously: it is the pre-clinical golden egg, extending lifespan across cells, worms, flies and mice, and there is a mechanistic case that older muscle over-activates mTOR complex 1 and starves itself of autophagy. A completed 13-week trial in adults aged 65 to 85 paired three exercise sessions a week with weekly low-dose sirolimus, primarily to check for harm rather than to prove benefit.
Even so, the researcher running that trial says he does not take rapamycin, has never prescribed it, and recommends it only inside approved indications or ethics-approved trials. The NAD story fares worse: muscle biopsy data suggest older adults who exercise have NAD levels comparable to younger adults, undercutting the premise that everyone needs a precursor, and placebo-controlled NMN and NR trials have been broadly underwhelming. High-dose niacin gets a nuanced re-examination, and the group closes on the supplements they actually find defensible — creatine, omega-3s, psyllium husk, betaine — plus a sober look at vitamin K2, magnesium and collagen peptides.
Key quotes
5Sometimes it's like 1% science and then 99% hype — there's almost nothing to back it up in some of these cases.
You've got two known risks for non-diabetics to take metformin and no potential benefit.
It's a lot easier to shorten a species' lifespan than to lengthen it.
I personally don't take rapamycin, nor have I ever prescribed it.
Diet, exercise, not smoking, sleep — that's the direction the Titanic is heading. These drugs are the song the band was playing.
Key ideas
9How the metformin hype began
Excitement traced back to a 2008 result in one inbred hypertensive mouse strain, plus observational data suggesting type 2 diabetics on metformin alone had lower heart disease rates. Neither was designed to answer whether healthy people should take it.
Replication changes the picture
A program that runs identical experiments in three separate labs using genetically diverse mice found no lifespan extension from metformin. Running the same study in parallel labs reveals whether a result is real or a quirk of one facility.
Twenty-one years of human data
A prevention trial started in 1997 followed high-risk but non-diabetic individuals on metformin or placebo for 21 years. No improvement appeared in all-cause mortality, cancer rates or cardiovascular disease.
Metformin can work against your training
Two randomized trials found that when both groups exercised, the metformin group captured only about half the gains in VO2 max and strength. Metformin also lowers testosterone levels.
Two molecules, one pathway
Metformin activates AMPK and affects mTOR complex 1 indirectly, while rapamycin — as sirolimus — targets mTOR complex 1 directly. That distinction matters because the lifespan effects are attributed to complex 1, not complex 2.
The autophagy hypothesis in aging muscle
Muscle biopsy studies suggest older adults over-activate mTOR complex 1, as if the muscle were straining to rebuild. The cost is suppressed autophagy, so damaged cellular components accumulate instead of being cleared.
A trial built to detect harm, not prove benefit
Forty adults aged 65 to 85 cycled Monday, Wednesday and Friday, then took weekly sirolimus or placebo on Saturday for 13 weeks, with the 30-second chair-stand test as the primary frailty marker. With that sample size, the goal is a safety signal and a justification for a larger study.
The NAD premise itself is shaky
A 2022 observational study comparing muscle biopsies found that older adults who exercised had NAD levels essentially matching younger adults. If diet, movement and sleep are in place, NAD may not be the deficit the marketing describes.
The niacin lesson repeats itself
High-dose niacin lowered LDL cholesterol but failed to lower heart disease rates, and later analysis pointed to pro-inflammatory metabolites that rise with mega-dosing. Lowering a marker is not the same as lowering risk.
Practical takeaways
7- 1
Don't blunt your own training 13:40
If you exercise and you are not diabetic, the evidence points to metformin costing you roughly half your VO2 max and strength gains. There is no matching upside on the other side of that trade.
- 2
Treat unproven molecules as experiments, not routines 36:20
The researcher closest to the rapamycin data neither takes it nor prescribes it outside approved indications and formal trials. Wait for human evidence before making yourself the study.
- 3
Exercise appears to protect NAD 39:30
Older adults who trained had muscle NAD comparable to younger adults. Movement, food and sleep look like the more reliable route than a precursor supplement.
- 4
Fix the big levers first 44:40
Diet, exercise, sleep and not smoking are the direction of travel; these molecules are decoration. Optimizing the decoration while the fundamentals are broken is the wrong order of operations.
- 5
The short list worth considering 45:50
Creatine stands out for effect size across multiple organ systems, with an added case for people eating mostly plant-based. Omega-3s matter mainly if oily fish is rare in your diet.
- 6
Psyllium husk is the underrated one 46:50
Most Western diets fall short on fiber, and a spoonful in a morning smoothie is an easy correction. Clinical guidelines suggest it for irritable bowel symptoms, and evidence points to effects on weight, inflammation and cholesterol.
- 7
Calcium score is a correlate, not a lever 48:00
Reducing arterial calcium is not automatically good, since calcified plaque tends to be more stable than mixed plaque. A statin can even raise the calcium score while stabilizing plaque.
Topics & chapters
15Hype versus science in the aging field
The ratio of evidence to excitement in longevity is worse than anywhere else in nutrition. Some molecules are promising; many are almost entirely narrative.
Where the metformin story started
One inbred mouse strain in 2008 and observational data in type 2 diabetics sparked the idea that healthy people should take it too.
Three labs, diverse mice, no effect
A replication program using genetically diverse mice across three simultaneous labs found no lifespan extension from metformin.
The 21-year human trial
A prevention trial in high-risk non-diabetics showed no benefit for mortality, cancer or cardiovascular disease over two decades.
The real cost of metformin in non-diabetics
Randomized data show blunted exercise adaptation and lower testosterone. For diabetics and pre-diabetics the calculation is entirely different.
AMPK, mTOR and where rapamycin fits
The two most-hyped molecules touch the same pathway from different angles, and the distinction between mTOR complex 1 and 2 matters.
The immunosuppression question
Rapamycin's clinical role in transplant medicine raises legitimate concerns about infection and cancer risk in otherwise healthy people.
Aging muscle, mTOR and autophagy
Older muscle appears to over-activate mTOR complex 1, potentially hoarding damaged components instead of clearing them.
Inside the rapamycin exercise trial
Forty adults aged 65 to 85, three cycling sessions a week, weekly dosing, 13 weeks, with the chair-stand test as the frailty marker.
Why sirolimus, and why six milligrams weekly
Absorption and selectivity for mTOR complex 1 drive the choice, and the weekly schedule is far below standard daily dosing.
A dose-dependent, paradoxical immune effect
High doses suppress immunity while low doses may stimulate it — influenza vaccine trials informed the safety case put to the ethics committee.
Who might benefit, and who shouldn't bother
If an effect exists, it likely appears from the fifties and sixties onward. Suppressing mTOR in a healthy, anabolic twenty-something makes little sense.
NAD, NMN and NR: the premise examined
Muscle biopsy data undercut the universal-decline story, and placebo-controlled trials of the precursors have been largely disappointing.
Niacin, biological clocks and the limits of proxies
Lowering LDL with niacin did not lower events, and epigenetic clocks remain too immature to steer decisions.
The supplements that survive scrutiny
Creatine, omega-3s, psyllium husk, betaine — plus a sober reassessment of vitamin K2, magnesium and collagen peptides.